The sheer volume of capital flowing into the biotech sector is a testament to the transformative potential of genetic medicine. Current Cell and Gene Therapy CDMO Market Size estimates suggest a multi-billion dollar industry that is only in its infancy. As the first wave of approved therapies moves from orphan drug status to broader indications, the demand for commercial-scale manufacturing capacity is expected to skyrocket, necessitating a new generation of "mega-factories."

However, size alone is not enough to guarantee success. The efficiency of the manufacturing process—measured by yield, purity, and turnaround time—will be the true differentiator. Companies that can demonstrate a lower "cost of goods sold" (COGS) will dominate the market, as healthcare payers demand lower prices for these high-cost treatments. The focus is shifting from "can we make it?" to "can we make it affordably and at scale?"

FAQ: How does manufacturing scale affect the price of gene therapy? Ans: Higher manufacturing scales allow for "economies of scale," reducing the fixed costs per dose and potentially making the therapies more affordable for insurance providers and patients.